India’s Aurobindo Pharma has notified that it has secured final approval from US Food and Drug Administration (USFDA) for marketing Topiramate tablets.

Aurbindo will market the pills in dosages of 25mg, 50mg, 100mg and 200mg.

The drug is prescribed for the treatment of epilepsy in both children and adults.

In many cases, the drug can also be used as an antidepressant, most of the time for depressive realism. In kids, it is also prescribed for treatment of Lennox-Gastaut syndrome, a disorder that causes seizures and developmental delay.

Recently, Aurobindo Pharma has secured tentative approval from US Food and Drug Administration (USFDA) for marketing generic lopinavir/ritonavir tablets.

The drugs are prescribed for the treatment of HIV-1 infection in adults and children above the age of two years. The tablets are used together with other anti-retroviral agents.

The company’s stock, on Friday (March 28), closed the week at Rs 174.10, up 2.6% on the Bombay Stock Exchange (BSE). The total volume of shares traded was 17,148. The share price has seen a 52-week high of Rs 360 and a low of Rs 101.60 on BSE.